LIVER FIBROSIS DIAGNOSIS: ARE THE METHODS PERFECT?


Cite item

Full Text

Abstract

High viral hepatitis morbidity, prevalence of overweight and alcohol abuse make the problem of early diagnosis of chronic liver diseases rather urgent. It is known that presence and degree of manifestation of liver fibrosis is of great significance for the choice of therapeutic tactics and assessment of prognosis for this category of patients. In the course of decades, biopsy was the only method for assessment of liver fibrosis. However, invasiveness and complexity of its realization, errors at the stage of interpreting morphological picture require development of noninvasive and precise methods for diagnosis of fibrosis. At present, there was suggested a number of instrumental and laboratory methods pretending to the role of “a perfect method”. Some instrumental methods demonstrate a high diagnostic accuracy but are expensive and need special equipment. Serum fibrosis markers, determined for today, are highly sensitive and specific only in case of marked fibrosis but they are low-informative for early diagnosis. Thus, searching of noninvasive, available and precise method for assessment of liver fibrosis is still going on.

Full Text

Диагностика фиброза печени: идеальны ли методы?
×

References

  1. Павлов Ч. С., Ивашкин В.Т. Биопсия печени: методология и практика сегодня. Рос. журн. гастроэнтерол. гепатол. колопроктол. 2006; 4: 65–78.
  2. Исаков В. А. Как определять выраженность фиброза печени и зачем? Клиническая гастроэнтерология и гепатология. Русское издание 2008; 2: 72–75.
  3. Северов М. В. Обратим ли цирроз печени? Клиническая гепатология 2006; 3: 3–9.
  4. Arun J., Jhala N., Lazenby A. J., Clements R., Abrams G.A. Influence of liver biopsy heterogeneity and diagnosis of nonalcoholic steatohepatitis in subjects undergoing gastric bypass. Obes. Surg. 2007; 2: 155–161.
  5. Asbach P., Klatt D., Schlosser B., Biermer M., Muche M., Rieger A., Loddenkemper C., Somasundaram R., Berg T., Hamm B., Braun J., Sack I. Viscoelasticity-based staging of hepatic fibrosis with multifrequency MR elastography. Radiology 2010; 1: 80–86.
  6. Bedossa P., Dargere D., Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 6: 1449–1457.
  7. Boeker K. H., Haberkorn C. I., Michels D., Flemming P., Manns M. P., Lichtinghagen R. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin. Chim. Acta. 2002; 1: 71–81.
  8. Bosselut N., Taibi L., Guechot J., Zarski J. P., Sturm N., Gelineau M.C., Poggi B., Thoret S., Lasnier E., Baudin B., Housset C., Vaubourdolle M., the ANRS HCEP 23 Fibrostar Group. Including osteoprotegerin and collagen IV in a score-based blood test for liver fibrosis increases diagnostic accuracy. Clin. Chim. Acta. 2013; 1: 63–68.
  9. Bravo A. A., Sheth S. G., Chopra S. Liver biopsy. N. Engl. J. Med. 2001; 7: 495–500.
  10. Cales P., de Ledinghen V., Halfon P., Bacq Y., Leroy V., Boursier J., Foucher J., Bourliеre M., de Muret A., Sturm N., Hunault G., Oberti F. Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int. 2008; 10: 1352–1362.
  11. Crisan D., Radu C., Lupsor M., Sparchez Z., Grigorescu M. D., Grigorescu M. Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis C; results from a cohort of 446 patients. Hepat. Mon. 2012; 3: 177–184.
  12. Friedman S. L. Liver fibrosis – from bench to bedside. J. Hepatol. 2003; 38, Suppl 1: 38–53.
  13. Friedrich-Rust M., Rosenberg W., Parkes J., Herrmann E., Zeuzem S., Sarrazin C. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol. 2010; 10: 103–105.
  14. Gabrielli G. B., Capra F., Casaril M., Squarzoni S., Tognella P., Dagradi R., De Maria E., Colombari R., Corrocher R., De Sandre G. Serum laminin and type III procollagen in chronic hepatitis C. Diagnostic value in the assessment of disease activity and fibrosis. Clin. Chim. Acta. 1997; 1: 21–31.
  15. Gao Y., Chen Z. B., Zheng S. S., Hu G. Z., Ding C. Y., Zhang Y., Zhao X. H., Ni L. M. Regression of liver fibrosis after biliary drainage in patients with choledocholith: a preliminary report. Hepatobiliary Pancreat Dis Int. 2005; 1: 104–107.
  16. Giannini E., Caglieris S., Ceppa P., Risso D., Lantieri P. B., Testa R. Serum pro-collagen III peptide levels are related to lobular necrosis in untreated patients with chronic hepatitis C. Eur. J. Gastroenterol. Hepatol. 2001; 2: 137–141.
  17. Giannini E., Fasoli A., Borro P. Применение экспираторных проб с 13С-галактозой и 13С-аминопирином для оценки функции печени при хронических заболеваниях печени. Клиническая гастроэнтерология и гепатология. Русское издание 2008; 2: 110–116.
  18. Guechot J., Lasnier E., Sturm N., Paris A., Zarski J. P. Automation of the Hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis C from the ANRS HC EP 23 Fibrostar cohort. Clin. Chim. Acta. 2010; 1: 86–91.
  19. Guha I. N., Parkes J., Roderick P., Chattopadhyay D., Cross R., Harris S., Kaye P., Burt A. D., Ryder S. D., Aithal G. P., Day C. P., Rosenberg W. M. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 2: 455–460.
  20. Halfon P., Bourliere M., Penaranda G. Accuracy of hyaluronic acid level for predicting liver fifibbrosis stages in patients with hepatitis C virus. Comp. Hepatol. 2005; 6: 1615–1635.
  21. Halfon P., Munteanu M., Poynard T. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol. Clin. Biol. 2008; 6: 22–39.
  22. Hirayama C., Yoshikawa T., Tada H. Serum-galactosamine. A diagnostic index of liver fibrosis in liver disease. Lancet 1961; 7176: 532–533.
  23. Jin W., Lin Z., Xin Y., Jiang X., Dong Q., Xuan S. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis: a leading meta-analysis. BMC Gastroenterol. 2012; 4.
  24. Johansen J. S. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan. Med. Bull. 2006; 2: 172–209.
  25. Kim B. H., Lee J. M., Lee Y. J., Lee K. B., Suh K. S., Han J. K., Choi B. I. MR elastography for noninvasive assessment of hepatic fibrosis: experience from a tertiary center in Asia. Radiology 2010; 1: 1110–1116.
  26. Kim B. K., Kim H. S., Park J. Y., Kim do Y., Ahn S. H., Chon C. Y., Park Y. N., Han K. H., Kim S. U. Prospective Validation of ELF Test in Comparison with Fibroscan and FibroTest to Predict Liver Fibrosis in Asian Subjects with Chronic Hepatitis B. PLoS One 2012; 7.
  27. Kim B. K., Kim S. U., Kim H. S., Park J. Y., Ahn S. H., Chon C. Y., Cho I. R., Joh D. H., Park Y. N., Han K. H., Kim do Y. Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B. PLoS. One 2012; 4.
  28. Kim B. K., Kim Y., Park J. Y., Ahn S. H., Chon C.Y., Kim J. K., Paik Y. H., Lee K. S., Park Y. N., Han K.H. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int. 2010; 4: 546–553.
  29. Kim W. R., Brown Jr. R. S. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002; 1: 227–242.
  30. Kruger F. C., Daniels C. R., Kidd M., Swart G., Brundyn K., van Rensburg C., Kotze M. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. S. Afr. Med. J. 2011; 7: 477–480.
  31. Leeming D., He Y., Veidal S., Nguyen Q., Larsen D., Koizumi M., Segovia-Silvestre T., Zhang C., Zheng Q., Sun S., Cao Y., Barkholt V., Hägglund P., Bay-Jensen A., Qvist P., Karsdal M. A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers 2011; 7: 616–628.
  32. Leroy V., Monier F., Bottari S., Trocme C., Sturm N., Hilleret M. N., Morel F., Zarski J. P. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am. J. Gastroenterol. 2004; 2: 271–279.
  33. Liu T., Wang X.,. Karsdal M. A., Leeming D. J., Genovese F. Molecular serum markers of liver fibrosis. Biomark Insights 2012; 7: 105–117.
  34. Liu X. D., Wu J. L., Liang J., Zhang T., Sheng Q. S. Globulin-platelet model predicts minimal fibrosis and cirrhosis in chronic hepatitis B virus infected patients. World J. Gastroenterol. 2012; 22: 2784–2792.
  35. McHutchison J. G., Blatt L. M., de Medina M. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J. Gastroenterol. Hepatol. 2000; 8: 945–951.
  36. Poynard T., Morra R., Halfon P., Castera L., Ratziu V., Imbert-Bismut F., Naveau S., Thabut D., Lebrec D., Zoulim F., Bourliere M., Cacoub P., Messous D., Munteanu M., de Ledinghen V. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol. 2007; 40.
  37. Poynard T., Ngo Y., Munteanu M., Thabut D., Massard J., Moussalli J., Varaud A., Benhamou Y., Ratziu V. Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies. Antivir. Ther. 2010; 4: 617–631.
  38. Poynard T., Ngo Y., Munteanu M., Thabut D., Ratziu V. Noninvasive markers of hepatic fibrosis in chronic hepatitis B. Curr. Hepat. Rep. 2011; 2: 87–97.
  39. Ratziu V., Massard J., Charlotte F., Messous D., Imbert-Bismut F., Bonyhay L., Tahiri M., Munteanu M., Thabut D., Cadranel J. F., Le Bail B., de Ledinghen V., Poynard T. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006; 6: 6–12.
  40. Regev A., Berho M., Jeffers L. J., Milikowski C., Molina E. G., Pyrsopoulos N. T., Feng Z. Z., Reddy K. R., Schiff E. R. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am. J. Gastroenterol. 2002; 10: 2614–2618.
  41. Rosenberg W. M., Voelker M., Thiel R., Becka M., Burt A., Schuppan D., Hubscher S., Roskams T., Pinzani M., Arthur M. J. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 6: 1704–1713.
  42. Saitou Y., Shiraki K., Yamanaka Y., Yamaguchi Y., Kawakita T., Yamamoto N., Sugimoto K., Murata K., Nakano T. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J. Gastroenterol. 2005; 4: 476–481.
  43. Shaheen A. A., Myers R. P. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007; 3: 912–921.
  44. Sheth S. G., Flamm S. L., Gordon F. D., Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am. J. Gastroenterol. 1998; 1: 44–48.
  45. Sporea I., Popescu A., Sirli R. Why, who and how should perform liver biopsy in chronic liver diseases. World J. Gastroenterol. 2008; 21: 3396–3402.
  46. Stebbing J., Farouk L., Panos G., Anderson M., Jiao L.R., Mandalia S., Bower M., Gazzard B., Nelson M. A meta-analysis of transient elastography for the detection of hepatic fibrosis. J. Clin. Gastroenterol 2010; 3: 214–219.
  47. Sterling R. K., Lissen E., Clumeck N., Sola R., Correa M. C., Montaner J., Sulkowski M., Torriani F. J., Dieterich D. T., Thomas D. L., Messinger D., Nelson M. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 6: 1317–1325.
  48. Sumida Y., Yoneda M., Hyogo H., Itoh Y., Ono M., Fujii H., Eguchi Y., Suzuki Y. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol. 2012; 12: 2–9.
  49. Szymczak A., Simon K., Inglot M., Gladysz A. Safety and effectiveness of blind percutaneous liver biopsy: analysis of 1412 procedures. Hepat Mon. 2012; 1: 32–37.
  50. Talwalkar J., Kurtz D. M., Schoenleber S. J., West C. P., Montoric V. M. Непрямая эластография печени с помощью ультразвука в диагностике фиброза: систематический обзор и метаанализ. Клиническая гастроэнтерология и гепатология. Русское издание 2008; 2: 76–83.
  51. Teare J. P., Sherman D., Greenfield S. M., Simpson J., Bray G., Catterall A. P., Murray-Lyon I. M., Peters T. J., Williams R., Thompson R.P. Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet 1993; 8876: 895–898.
  52. Vallet-Pichard A., Mallet V., Nalpas B., Verkarre V., Nalpas A., Dhalluin-Venier V., Fontaine H., Pol S. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007; 1: 32–36.
  53. Vassiliadis E., Larsen D. V., Clausen R. E., Veidal S. S., Barascuk N., Larsen L., Simonsen H., Silvestre T. S., Hansen C., Overgaard T., Leeming D. J., Karsdal M. A. Measurement of CO3-610, a potential liver biomarker derived from matrix metalloproteinase-9 degradation of collagen type III, in a rat model of reversible carbon-tetrachloride-induced fibrosis. Biomark. Insights 2011; 6: 49–58.
  54. Yilmaz Y., Yonal O., Kurt R., Bayrak M., Aktas B., Ozdogan O. Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease: APRI in chronic liver disease. Hepat. Mon. 2011; 2: 103–106.
  55. Yin M., Talwalkar J. A., Glaser K. J., Manduca A., Grimm R. C., Rossman P. J., Fidler J. L., Ehman R. L. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin. Gastroenterol. Hepatol. 2007; 10: 1207–1213.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Shirokikh I.N., Mavlitova L.A., Tuev A.V., Khlynova O.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 70264 от 13.07.2017 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 75489 от 05.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies